Tyra Biosciences, Inc. (TYRA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$20.45-2.01%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tyra Biosciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.675
Annual ending 2026-12-31
Revenue	—	687,429
EPS	—	-2.652
Annual ending 2027-12-31
Revenue	—	3.38M
EPS	—	-2.8

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve earnings losses toward consensus estimates	A supporting condition in Tyra Biosciences, Inc.'s published investment case. The stated target is EPS loss narrows toward -2.55 in FY26 and -2.82 in FY27.	Broken	EPS losses worsen beyond -2.55 in FY26 or -2.82 in FY27	Diluted EPS: $-0.69 per share FY2026-Q2; GAAP. Published target: EPS loss narrows toward -2.55 in FY26 and -2.82 in FY27. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-0.69 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 83487324-c79a-431f-894d-8fcd5470d66e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Report initial three-month complete response data by August 2026	Tyra aims to report initial response data in August 2026.	Intact	Initial response data is not reported by August 2026	57.0% CR reported vs target of reporting by 2026-08 SURF302 Phase 2 data reported Sept 9, 2026, showing 57% complete response rate, confirming initial data delivery. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Release initial safety sentinel cohort results by Q4 2026	They plan safety data from a sentinel cohort by Q4 2026.	Improving	Safety sentinel results are not released by Q4 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.80

$-2.87 → $-2.80 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.87	$3,381,818	12 / 8
2026-07-25	$-2.87	$3,381,818	12 / 8
2026-07-26	$-2.87	$3,381,818	12 / 8
2026-07-27	$-2.87	$3,381,818	12 / 8
2026-07-28	$-2.87	$3,381,818	12 / 8
2026-07-29	$-2.87	$3,381,818	12 / 8
2026-07-30	$-2.86	$3,100,000	14 / 12
2026-07-31	$-2.87	$3,381,818	12 / 8
2026-08-01	$-2.87	$3,381,818	12 / 8
2026-08-02	$-2.86	$3,100,000	14 / 12
2026-08-03	$-2.87	$3,381,818	12 / 8
2026-08-04	$-2.87	$3,381,818	12 / 8
2026-08-05	$-2.86	$3,100,000	14 / 12
2026-08-06	$-2.87	$3,381,818	12 / 8
2026-08-08	$-2.97	$3,381,818	12 / 6
2026-08-09	$-2.92	$0	14 / 12
2026-08-10	$-2.97	$3,381,818	12 / 6
2026-08-12	$-2.97	$3,381,818	12 / 6
2026-08-13	$-2.95	$0	14 / 12
2026-08-14	$-2.97	$3,381,818	12 / 6
2026-08-15	$-2.97	$3,381,818	12 / 6
2026-08-16	$-2.97	$3,381,818	12 / 6
2026-08-17	$-2.97	$3,381,818	12 / 6
2026-08-18	$-2.97	$3,381,818	12 / 6
2026-08-19	$-2.97	$3,381,818	12 / 6
2026-08-20	$-2.98	$3,381,818	12 / 8
2026-08-21	$-2.98	$3,381,818	12 / 8
2026-08-22	$-2.98	$3,381,818	12 / 8
2026-08-23	$-2.98	$3,381,818	12 / 8
2026-08-24	$-2.98	$3,381,818	12 / 8
2026-08-25	$-2.98	$3,381,818	12 / 8
2026-08-26	$-2.98	$3,381,818	12 / 8
2026-08-27	$-2.98	$3,381,818	12 / 8
2026-08-28	$-2.98	$3,381,818	12 / 8
2026-08-29	$-2.98	$3,381,818	12 / 8
2026-08-30	$-2.98	$3,381,818	12 / 8
2026-08-31	$-2.98	$3,381,818	12 / 8
2026-09-01	$-2.98	$3,381,818	12 / 8
2026-09-02	$-2.98	$3,381,818	12 / 8
2026-09-03	$-2.98	$3,381,818	12 / 8
2026-09-04	$-2.98	$3,381,818	12 / 8
2026-09-05	$-2.98	$3,381,818	12 / 8
2026-09-06	$-2.98	$3,381,818	12 / 8
2026-09-07	$-2.98	$3,381,818	12 / 8
2026-09-08	$-2.98	$3,381,818	12 / 8
2026-09-09	$-2.98	$3,381,818	12 / 8
2026-09-10	$-2.98	$3,381,818	12 / 8
2026-09-11	$-2.91	$3,381,818	12 / 8
2026-09-12	$-2.91	$3,381,818	12 / 8
2026-09-13	$-2.91	$3,381,818	12 / 8
2026-09-14	$-2.91	$3,381,818	12 / 8
2026-09-15	$-2.91	$3,381,818	12 / 8
2026-09-16	$-2.90	$3,381,818	12 / 8
2026-09-17	$-2.90	$3,381,818	12 / 8
2026-09-18	$-2.90	$3,381,818	12 / 8
2026-09-19	$-2.90	$3,381,818	12 / 8
2026-09-20	$-2.90	$3,381,818	12 / 8
2026-09-21	$-2.90	$3,381,818	12 / 8
2026-09-22	$-2.90	$3,381,818	12 / 8
2026-09-23	$-2.80	$3,381,818	12 / 8
2026-09-24	$-2.80	$3,381,818	12 / 8
2026-09-25	$-2.80	$3,381,818	12 / 8
2026-09-26	$-2.80	$3,381,818	12 / 8
2026-09-27	$-2.80	$3,381,818	12 / 8
2026-09-28	$-2.80	$3,381,818	12 / 8
2026-09-29	$-2.80	$3,381,818	12 / 8
2026-09-30	$-2.80	$3,381,818	12 / 8
2026-10-01	$-2.80	$3,381,818	12 / 8
2026-10-02	$-2.80	$3,381,818	12 / 8
2026-10-03	$-2.80	$3,381,818	12 / 8
2026-10-04	$-2.80	$3,381,818	12 / 8
2026-10-05	$-2.80	$3,381,818	12 / 8
2026-10-06	$-2.80	$3,381,818	12 / 8
2026-10-07	$-2.80	$3,381,818	12 / 8
2026-10-08	$-2.80	$3,381,818	12 / 8
2026-10-09	$-2.80	$3,381,818	12 / 8
2026-10-10	$-2.80	$3,381,818	12 / 8
2026-10-11	$-2.80	$3,381,818	12 / 8
2026-10-12	$-2.80	$3,381,818	12 / 8
2026-10-13	$-2.80	$3,381,818	12 / 8
2026-10-14	$-2.80	$3,381,818	12 / 8
2026-10-15	$-2.80	$3,381,818	12 / 8
2026-10-16	$-2.80	$3,381,818	12 / 8
2026-10-17	$-2.80	$3,381,818	12 / 8
2026-10-18	$-2.80	$3,381,818	12 / 8
2026-10-19	$-2.80	$3,381,818	12 / 8
2026-10-20	$-2.80	$3,381,818	12 / 8
2026-10-21	$-2.80	$3,381,818	12 / 8
2026-10-22	$-2.80	$3,381,818	12 / 8
2026-10-23	$-2.80	$3,381,818	12 / 8
2026-10-24	$-2.80	$3,381,818	12 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	13	1
2026-06-01	14	1
2026-07-01	14	1
2026-08-01	14	1
2026-09-01	14	1
2026-10-01	14	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Raymond JamesOct 6

$50.00New observation · no comparable prior

$0$27.50$55.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve earnings losses toward consensus estimatesPublished status: Broken
Release initial safety sentinel cohort results by Q4 2026Qualitative condition

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-53.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tyra Biosciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

TYRA is a high-risk clinical-stage biotech, not a proven earnings compounder: it is loss-making and reports no revenue in the evidence provided. Its long-term thesis is on watch, with confidence in the overall assessment low.

What's priced into Tyra Biosciences, Inc.

The snapshot does not provide a valuation level or clear evidence of what market expectations already assume, so whether TYRA looks cheap, fair, or expensive versus peers is unclear. It reports no fragility signals, but that does not establish that expectations are modest.

What the fundamentals likely do

Near term, weak recent performance, a recent earnings miss, and an elevated risk of another miss point to continued uncertainty. Management remains focused on its clinical programs, with initial SURF302 data reported as on track for 2026; BEACH301’s initial results timing shifted to the end of Q1 2027, while progress on the dabogratinib studies is mixed.

What Tyra Biosciences, Inc. hinges on

The multi-year thesis hinges on whether TYRA can advance its clinical programs and produce useful data, including from SURF302 and BEACH301. Near-term risks include a guidance cut and continued weak results; stronger sector momentum is a possible support, but it does not resolve company-specific execution risk.